Studying Gene Expression in Tissue Samples From Patients With Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01057095|
Recruitment Status : Completed
First Posted : January 27, 2010
Last Update Posted : October 2, 2015
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at gene expression in tissue samples from patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: RNA analysis Genetic: gene expression analysis Genetic: reverse transcriptase-polymerase chain reaction Other: laboratory biomarker analysis|
- Screen acute myeloid leukemia (AML) samples to correlate high relative expression levels of PLAGL2 and putative PLAGL2 target genes (implicated in microarray study) with potential pathogenic relevance with respect to AML development.
OUTLINE: Cryopreserved mRNA from diagnostic samples is analyzed for gene expression by reverse transcriptase-PCR.
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||Mechanisms of PLAGL2-Induced Leukaemogenesis|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||April 2010|
|Actual Study Completion Date :||April 2010|
- Correlation of high relative expression levels of PLAGL2 and putative PLAGL2 target genes with potential pathogenic relevance
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01057095
|Principal Investigator:||Soheil Meshinchi, MD||Fred Hutchinson Cancer Research Center|